Get started
Author

Valerie Lydia Bowering

Observed names: Bowering, Valerie, V. Bowering, V.L. Bowering, Valerie Bowering
ORCID: 0000-0003-0910-5186
Observed ORCID: 0000-0003-0910-5186
OpenAlex ID: A5021338846
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
2021 · Stephanie Lheureux, Mihaela C Cristea, et al. · The Lancet · 221
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
2020 · Stephanie Lheureux, Ana Oaknin, et al. · Clinical Cancer Research · 134
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
2017 · Stephanie Lheureux, Jeff P. Bruce, et al. · Journal of Clinical Oncology · 92
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
2020 · Ainhoa Madariaga, Valerie Bowering, et al. · International Journal of Gynecological Cancer · 86
PDF
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2023 · Stephanie Lheureux, Stephenie D. Prokopec, et al. · Clinical Cancer Research · 41
PDF
Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer
2019 · Yeh Chen Lee, Nazlin Jivraj, et al. · Journal of Oncology Practice · 31
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
2023 · Ainhoa Madariaga, Swati Garg, et al. · Nature Communications · 29
PDF
A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.
2022 · Stephanie Lheureux, Husam Alqaisi, et al. · Journal of Clinical Oncology · 22
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
2022 · Stefano Marastoni, Ainhoa Madariaga, et al. · Cancer Research Communications · 21
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
2025 · Husam A. Alqaisi, David E. Cohn, et al. · Clinical Cancer Research · 20
PDF
2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation
2015 · R. Shapira-Frommer, A. Oza, et al. · European Journal of Cancer · 20
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention
2016 · Katherine Karakasis, Julia V. Burnier, et al. · Frontiers in Oncology · 18
PDF
Safety evaluation of olaparib for treating ovarian cancer
2015 · Stephanie Lheureux, Valerie Bowering, et al. · Expert Opinion on Drug Safety · 18
A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation.
2015 · Ronnie Shapira-Frommer, Amit M. Oza, et al. · Journal of Clinical Oncology · 17
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers
2023 · Eduardo Gonzalez-Ochoa, Michael Milosevic, et al. · International Journal of Gynecological Cancer · 16
Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study
2020 · Maria C. Cusimano, Katrina Sajewycz, et al. · Gynecologic Oncology · 15
Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.
2019 · Stephanie Lheureux, Ana Oaknin, et al. · Journal of Clinical Oncology · 14
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma
2022 · Ainhoa Madariaga, Sandra A. Mitchell, et al. · Gynecologic Oncology · 13
Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial.
2022 · Ana Veneziani, Stephanie Lheureux, et al. · Journal of Clinical Oncology · 11
Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences
2021 · Ainhoa Madariaga, Gita Bhat, et al. · American Journal of Obstetrics and Gynecology · 9
Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.
2021 · Ainhoa Madariaga, Swati Garg, et al. · Journal of Clinical Oncology · 9
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative
2025 · Tess Aalto, Maria Abacan, et al. · Cancer Cell · 6
Circulating human papillomavirus DNA sequencing as a biomarker of response in advanced cervical cancer
2025 · Emma Collier, Pamela Soberanis Pina, et al. · International Journal of Gynecological Cancer · 6
PDF
Phase I/II trial assessing hydroxychloroquine and itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-01).
2020 · Ainhoa Madariaga, Stefano Marastoni, et al. · Journal of Clinical Oncology · 6
A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia.
2015 · Stephanie Lheureux, Johanne Ingrid Weberpals, et al. · Journal of Clinical Oncology · 5
Works count: 158
Citation count: 916
H-index: 15
I10-index: 19
Year
Topic
Type